Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)

Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)

Scope of the Report

The report entitled “Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)”, provides an analysis of global biosimilar market in terms of value. The report also provides a brief analysis of the global biologics market by value and market share by products.

Furthermore, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global biosimilar market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Sandoz, Amgen, Celltrion and Pfizer are some of the key players operating in the global biosimilar market whose company profiling has been done in the report. This segment of the report summarizes business overview, financial overview and the business strategies of the companies.

Company Coverage


Executive Summary

Majority of biosimilars are in pipeline as most of the major biologics have either already expired or are about to lose their patent in the next two years which act as a major driving force for the biosimilar market. Four major biologics namely Humira, Enbrel, Remicade and Infliximab patents are set to expire in December 2016, incentivizes a large number of companies to enter into biosimilar market.

The biosimilar market is in its early stages, but is expected to grow in the next five years. The global biosimilar market is supported by various growth drivers such as growing pressure to curtail healthcare expenditure, patent expiries of major biopharmaceuticals, rising chronic disease among aging population and positive outcomes in ongoing clinical trials etc. Yet the market faces some challenges, such as restrict entry of new players, the complexity of manufacturing biosimilars and clinical limitations including patient recruitment obstacles.

1. Executive Summary
2. Introduction
2.1 Overview of Pharmaceutical Industry
2.2 Overview of Biologics
2.2.1 Difference between Chemical Drugs Vs 1st Gen Vs 2nd Gen Biologics
Table A: Chemical Drugs Vs 1st Generation Biologics Vs 2nd Generation Biologics
2.2.2 Methods of Biologics Manufacturing
Table 1: Biologics Manufacturing Method
2.2.3 Top 5 Biologics Drugs
Table B: Top 5 Biologics Drugs
2.3 Overview of Biosimilars
Table C: US Approved Biosimilars
2.3.1 Difference between Biosimilars and Generics
Table D: Biosimilars Vs Generics
3. Global Market Analysis
3.1 Global Pharmaceutical Market Analysis
3.1.1 Global Pharmaceutical Market by Value
Table 2: Global Pharmaceutical Market by Value; 2015-2020E (US$ Billion)
3.1.2 Global Pharmaceutical Sales: Biotech Vs Conventional Technology
Table 3: Global Pharmaceutical Sales- Biotech Vs Conventional Technology;
3.2 Global Biologics Market Analysis
3.2.1 Global Biologics Market by Value
Table 4: Global Biologics Market by Value; 2010-2015 (US$ Billion)
Table 5: Global Biologics Market by Value; 2016-2020E (US$ Billion)
3.2.2 Global Biologics Market Share by Products
Table 6: Global Biologics Market Share by Products; 2015
3.3 Global Biosimilar Market Analysis
3.3.1 Global Biosimilar Market by Value
Table 7: Global Biosimilar Market by Value; 2015-2020E (US$ Billion)
3.3.2 Major Biosimilars in the Pipeline
Table E: Biosimilars in the Pipeline
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Growing Pressure to Curtail Healthcare Expenditure
Table 8: Global Health Expenditure (% of Total GDP); 2010-2014
4.1.2 Patent Expiries of Major Biopharmaceuticals
Table F: Leading Biologic Products with Patent Expiries; 2014-2020
4.1.3 Positive Outcomes in Ongoing Clinical Trials
4.1.4 Rising Demand for Biosimilars in Therapeutic Application
4.1.5 Rising Chronic Disease among Aging Population
Table 9: Global Aging Population; 2000-2015 (Million)
4.2 Challenges
4.2.1 Restrict Entry of New Players
4.2.2 Complexity of Expertise
4.2.3 Regulatory Challenges
Table G: Countries with Specific Biosimilar Guidelines
4.2.4 Market Penetration Issue of Orphan Biosimilars
4.2.5 Clinical Limitations Including Patient Recruitment Obstacles
4.3 Market Trends
4.3.1 Emergence of New Market Participants
4.3.2 Inclusion of Drug Delivery Device
4.3.3 Uberization of Healthcare Industry
4.3.4 Increasing Use of Single-Use Technology
5. Competitive Landscape
5.1 Global Biologics Market Sales by Drugs
Table 10: Global Biologics Market Sales by Drugs; 2015
6. Company Profiling
6.1 Sandoz
6.1.1 Business Overview
Table H: Sandoz Major Biosimilar Pipeline
6.1.2 Financial Overview
Table 11: Sandoz Revenue; 2010-2015 (US$ Billion)
Table 12: Sandoz Revenue by Segment; 2015
6.1.3 Business Strategy
6.2 Amgen
6.2.1 Business Overview
Table I: Amgen Major Biosimilar Pipeline
6.2.2 Financial Overview
Table 9: Amgen Major Biosimilar Pipeline
6.2.3 Business Strategy
6.3 Celltrion
6.3.1 Business Overview
Table J: Celltrion Major Biosimilar Pipeline
6.3.2 Financial Overview
Table 15: Celltrion Revenue; 2012-2015 (US$ Billion)
6.3.3 Business Strategy
6.4 Pfizer
6.4.1 Business Overview
Table K: Pfizer Major Biosimilar Pipeline
6.4.2 Financial Overview
Table 16: Pfizer Revenue; 2012-2015 (US$ Billion)
Table 17: Pfizer Revenue by Geography; 2015
6.4.3 Business Strategy

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook